Follow Us

News

Home / News

News

Home / News

2025

Breaking News

GC LabTech, Inc. (GCLT, San Antonio, TX, USA) closed out a successful 2024! Poised for more growth in 2025, GCLT has selected the recently US-FDA Approved Donor Screening Serology Platform from Roche Diagnostics. GCLT will soon begin transitioning its Viral Marker Testing from the Quidel Ortho Verseia Integrated Platform to the Roche Diagnostics Cobas® Pro Serology Solution. The addition of the Roche Serology Platform will further strengthen GCLT’s relationship with Roche Diagnostics, which also provides the Nucleic Acid Testing platform required for plasma donor screening.
In 2024, Quidel Ortho announced a Phased-Out departure from Donor Testing.

Breaking News

GC LabTech, Inc. (GCLT, San Antonio, TX, USA) has reached 500 followers on LinkedIn! Thank you to those who are following GCLT’s journey, seeing our progress and learning more about our services! Please like and share GCLT’s posts with friends and colleagues, we’re excited to share our story with our followers! …Stay tuned for more GCLT updates!

***Follow GCLT on LinkedIn for all Updates, News, and Announcements!***